| Nov 6 |
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
|
| Nov 6 |
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
|
| Nov 6 |
Jazz: Q3 Earnings Snapshot
|
| Nov 6 |
Jazz Pharmaceuticals Non-GAAP EPS of $6.61 beats by $1.11, revenue of $1.05B beats by $10M
|
| Nov 6 |
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
|
| Nov 5 |
Jazz Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 4 |
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics
|
| Oct 31 |
Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
|
| Oct 31 |
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
| Oct 30 |
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
|
